Richard Snyder, MD, executive vice president of Facilitated Health Networks and chief medical officer at Independence Blue Cross, discusses how the increasing share of novel, costly therapies will impact the prevalence of value-based agreements.
Richard Snyder, MD, executive vice president of Facilitated Health Networks and chief medical officer at Independence Blue Cross, discusses how the increasing share of novel, costly therapies will impact the prevalence of value-based agreements.
Transcript
With more novel, costly therapies being approved and patients being responsible for more costs, how do you think this will impact the prevalence and popularity of value-based agreements?
I think it will absolutely increase the speed to value-based care and also the kinds of arrangements that we will see going forward. There are quite a few creative ideas emerging. Amongst them the Blue Cross Blue Shield Association has a number of direct contracting type models to eliminate the need for a provider to invest in the cost of a medication and to thereby gain perhaps somewhat of a discount and facilitate the patient care delivery without incurring as much out of pocket costs for the patient.
Dr Kathryn Lindley Explains the Importance of Cardio-Obstetrics in Fellowship Programs
December 5th 2023Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, talks about why it’s important to incorporate cardio-obstetrics training into cardiovascular disease fellowship programs.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Christine Pfaff on Ensuring Patient Access to Affordable Treatments
October 17th 2023To ensure patients are getting timely access to their treatments, there needs to be better collaboration between payers and providers, said Christine Pfaff, RPh, senior regional director of operations, American Oncology Network.
Read More